KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) Equity Average (2020 - 2025)

Ginkgo Bioworks Holdings' Equity Average history spans 6 years, with the latest figure at $534.2 million for Q4 2025.

  • For Q4 2025, Equity Average fell 29.43% year-over-year to $534.2 million; the TTM value through Dec 2025 reached $534.2 million, down 29.43%, while the annual FY2025 figure was $612.3 million, 32.46% down from the prior year.
  • Equity Average reached $534.2 million in Q4 2025 per DNA's latest filing, down from $586.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.7 billion in Q1 2023 to a low of $375.7 million in Q2 2021.
  • Average Equity Average over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2021.
  • Peak YoY movement for Equity Average: soared 324.77% in 2022, then plummeted 41.49% in 2024.
  • A 5-year view of Equity Average shows it stood at $1.6 billion in 2021, then decreased by 0.16% to $1.6 billion in 2022, then fell by 26.11% to $1.2 billion in 2023, then crashed by 35.57% to $757.0 million in 2024, then dropped by 29.43% to $534.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Equity Average are $534.2 million (Q4 2025), $586.4 million (Q3 2025), and $630.2 million (Q2 2025).